Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    David M Harlan MD

    TitleProfessor
    InstitutionUniversity of Massachusetts Medical School
    DepartmentMedicine
    AddressUniversity of Massachusetts Medical School
    55 Lake Avenue North
    Worcester MA 01655
      Other Positions
      InstitutionUMMS - School of Medicine
      DepartmentPediatrics

      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentMasters in Clinical Investigation

        Overview 
        Narrative

        EDUCATION

        • Medical School, Duke University School of Medicine, Durham, North Carolina
        • Residency in Medicine, Duke University Medical Center, Durham, North Carolina
        • Fellowship in Endocrinology, Duke University Medical Center, Durham, NC

        ACADEMIC ROLE, FACULTY APPOINTMENT, CLINICAL ROLE

        • Chief, Diabetes, UMass Memorial Medical Center
        • Co-Director, Diabetes Center of Excellence, UMass Memorial Medical Center
        • Professor of Medicine, University of Massachusetts Medical School
        • Director, Diabetes Reserach Center, University of Massachusetts Medical School

        RESEARCH INTERESTS

        • Tolerance mechanisms and organ/tissue transplantation
        • Autoimmune illnesses, especially insulin dependent diabetes mellitus
        • Human beta cell biology
        • Improving diabetes care delivery systems



        Bibliographic 
        selected publications
        List All   |   Timeline
        1. Burbelo PD, Lebovitz EE, Bren KE, Bayat A, Paviol S, Wenzlau JM, Barriga KJ, Rewers M, Harlan DM, Iadarola MJ. Extrapancreatic autoantibody profiles in type I diabetes. PLoS One. 2012; 7(9):e45216.
          View in: PubMed
        2. Feigenbaum K, Brooks PG, Chamberlain CE, Cochran E, Adams-McLean A, Malek R, Harlan DM. The Clinical Center's Blood Glucose Management Service: A Story in Quality Integrated Care. Diabetes Educ. 2012 Mar; 38(2):194-206.
          View in: PubMed
        3. Greiner DL, Brehm MA, Hosur V, Harlan DM, Powers AC, Shultz LD. Humanized mice for the study of type 1 and type 2 diabetes. Ann N Y Acad Sci. 2011 Dec; 1245(1):55-8.
          View in: PubMed
        4. Soleimanpour SA, Hirshberg B, Bunnell DJ, Sumner AE, Ader M, Remaley AT, Rother KI, Rickels MR, Harlan DM. Metabolic function of a suboptimal transplanted islet mass in nonhuman primates on rapamycin monotherapy. Cell Transplant. 2012; 21(6):1297-304.
          View in: PubMed
        5. Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011 Apr; 13(4):457-60.
          View in: PubMed
        6. Rother KI, Harlan DM. Comment on: Keenan et al. (2010) Residual Insulin Production and Pancreatic {beta}-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853. Diabetes. 2010 Dec; 59(12):e26.
          View in: PubMed
        7. Harlan DM, Lee MM. Infant formula, autoimmune triggers, and type 1 diabetes. N Engl J Med. 2010 Nov 11; 363(20):1961-3.
          View in: PubMed
        8. Perl S, Kushner JA, Buchholz BA, Meeker AK, Stein GM, Hsieh M, Kirby M, Pechhold S, Liu EH, Harlan DM, Tisdale JF. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010 Oct; 95(10):E234-9.
          View in: PubMed
        9. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul; 33(7):1674-85.
          View in: PubMed
        10. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010 Jul-Aug; 60(4):207-21.
          View in: PubMed
        11. Pechhold S, Stouffer M, Walker G, Martel R, Seligmann B, Hang Y, Stein R, Harlan DM, Pechhold K. Transcriptional analysis of intracytoplasmically stained, FACS-purified cells by high-throughput, quantitative nuclease protection. Nat Biotechnol. 2009 Nov; 27(11):1038-42.
          View in: PubMed
        12. Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec; 32(12):2251-7.
          View in: PubMed
        13. Harlan DM, Kenyon NS, Korsgren O, Roep BO. Current advances and travails in islet transplantation. Diabetes. 2009 Oct; 58(10):2175-84.
          View in: PubMed
        14. Khan MH, Harlan DM. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care. 2009 Aug; 32(8):1570-4.
          View in: PubMed
        15. Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care. 2009 Jul; 32(7):1250-5.
          View in: PubMed
        16. Craig AT, Gavrilova O, Dwyer NK, Jou W, Pack S, Liu E, Pechhold K, Schmidt M, McAlister VJ, Chiorini JA, Blanchette-Mackie EJ, Harlan DM, Owens RA. Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors. Virol J. 2009; 6:61.
          View in: PubMed
        17. Liu EH, Digon BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, Kam A, Wesley RA, Polly SM, Hofmann RM, Rother KI, Harlan DM. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009 Jul; 52(7):1369-80.
          View in: PubMed
        18. Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One. 2009; 4(4):e4897.
          View in: PubMed
        19. Pechhold K, Koczwara K, Zhu X, Harrison VS, Walker G, Lee J, Harlan DM. Blood glucose levels regulate pancreatic beta-cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. PLoS One. 2009; 4(3):e4827.
          View in: PubMed
        20. Lin HM, Lee JH, Yadav H, Kamaraju AK, Liu E, Zhigang D, Vieira A, Kim SJ, Collins H, Matschinsky F, Harlan DM, Roberts AB, Rane SG. Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J Biol Chem. 2009 May 1; 284(18):12246-57.
          View in: PubMed
        21. Pechhold K, Zhu X, Harrison VS, Lee J, Chakrabarty S, Koczwara K, Gavrilova O, Harlan DM. Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes. 2009 May; 58(5):1175-84.
          View in: PubMed
        22. Pechhold K, Chakrabarty S, Harlan DM. Cytotoxic T cell-mediated diabetes in RIP-CD80 transgenic mice: autoantigen peptide sensitivity and fine specificity. Ann N Y Acad Sci. 2007 Apr; 1103:132-42.
          View in: PubMed
        23. Perl S, Hirshberg B, Harlan DM, Tisdale JF. How much insulin is enough? A quantitative assessment of the transdifferentiaton potential of liver. Diabetologia. 2007 Mar; 50(3):690-2.
          View in: PubMed
        24. Ren J, Jin P, Wang E, Liu E, Harlan DM, Li X, Stroncek DF. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transl Med. 2007; 5:1.
          View in: PubMed
        25. Liu EH, Siegel RM, Harlan DM, O'Shea JJ. T cell-directed therapies: lessons learned and future prospects. Nat Immunol. 2007 Jan; 8(1):25-30.
          View in: PubMed
        26. Taylor-Fishwick DA, Bowman A, Hamblet N, Bernard P, Harlan DM, Vinik AI. Islet neogenesis associated protein transgenic mice are resistant to hyperglycemia induced by streptozotocin. J Endocrinol. 2006 Sep; 190(3):729-37.
          View in: PubMed
        27. Neeman Z, Hirshberg B, Harlan D, Wood BJ. Radiologic aspects of islet cell transplantation. Curr Diab Rep. 2006 Aug; 6(4):310-5.
          View in: PubMed
        28. Dy EC, Harlan DM, Rother KI. Assessment of islet function following islet and pancreas transplantation. Curr Diab Rep. 2006 Aug; 6(4):316-22.
          View in: PubMed
        29. Bagenstose LM, Agarwal RK, Silver PB, Harlan DM, Hoffmann SC, Kampen RL, Chan CC, Caspi RR. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol. 2005 Jul 1; 175(1):124-30.
          View in: PubMed
        30. Harlan DM, von Herrath M. Immune intervention with anti-CD3 in diabetes. Nat Med. 2005 Jul; 11(7):716-8.
          View in: PubMed
        31. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9.
          View in: PubMed
        32. Kang EM, Zickler PP, Burns S, Langemeijer SM, Brenner S, Phang OA, Patterson N, Harlan D, Tisdale JF. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol. 2005 Jun; 33(6):699-705.
          View in: PubMed
        33. Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, Powers AC. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem. 2005 Sep; 53(9):1087-97.
          View in: PubMed
        34. Fowler M, Virostko J, Chen Z, Poffenberger G, Radhika A, Brissova M, Shiota M, Nicholson WE, Shi Y, Hirshberg B, Harlan DM, Jansen ED, Powers AC. Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation. 2005 Apr 15; 79(7):768-76.
          View in: PubMed
        35. Liu EH, Rother KI, Harlan DM. Islet transplantation and the challenges of treating type 1 diabetes. Discov Med. 2005 Feb; 5(25):43-9.
          View in: PubMed
        36. Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med. 2004 Dec; 1(3):e58; quiz e75.
          View in: PubMed
        37. Minn AH, Lan H, Rabaglia ME, Harlan DM, Peculis BA, Attie AD, Shalev A. Increased insulin translation from an insulin splice-variant overexpressed in diabetes, obesity, and insulin resistance. Mol Endocrinol. 2005 Mar; 19(3):794-803.
          View in: PubMed
        38. Neeman Z, Hirshberg B, Tal MG, Wood BJ, Harlan DM. Pulmonary angiography for the diagnosis of thromboembolic events in the non-human primate. Transplantation. 2004 Oct 15; 78(7):1025-9.
          View in: PubMed
        39. Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, Kirk AD, Burkly LC, Taylor FR. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 2004 Nov; 16(11):1583-94.
          View in: PubMed
        40. Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest. 2004 Oct; 114(7):877-83.
          View in: PubMed
        41. Harlan DM, Rother KI. Islet transplantation as a treatment for diabetes. N Engl J Med. 2004 May 13; 350(20):2104; author reply 2104.
          View in: PubMed
        42. Shalev A, Patterson NB, Hirshberg B, Rother KI, Harlan DM. Resistin serum levels in type 1 diabetes pre- and post-islet transplantation. Metabolism. 2004 Apr; 53(4):403-4.
          View in: PubMed
        43. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33.
          View in: PubMed
        44. Harlan DM. Gene-altered islets for transplant: giant leap or small step? Endocrinology. 2004 Feb; 145(2):463-6.
          View in: PubMed
        45. Minn AH, Kayton M, Lorang D, Hoffmann SC, Harlan DM, Libutti SK, Shalev A. Insulinomas and expression of an insulin splice variant. Lancet. 2004 Jan 31; 363(9406):363-7.
          View in: PubMed
        46. Tal MG, Hirshberg B, Neeman Z, Bunnell D, Soleimanpour S, Bacher J, Patterson N, Chang R, Harlan DM. Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of streptozotocin. Radiology. 2004 Jan; 230(1):163-8.
          View in: PubMed
        47. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003 Dec 3; 290(21):2817-23.
          View in: PubMed
        48. Hirshberg B, Rother KI, Digon III BJ, Venstrom J, Harlan DM. State of the art: islet transplantation for the cure of type 1 diabetes mellitus. Rev Endocr Metab Disord. 2003 Dec; 4(4):381-9.
          View in: PubMed
        49. Hirshberg B, Rother KI, Digon BJ, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003 Dec; 26(12):3288-95.
          View in: PubMed
        50. Kayton ML, Costouros NG, Lorang D, Alexander HR, Hewitt SM, Cochran C, Shalev A, Harlan D, Skarulis MC, Gorden P, Libutti SK. Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas. Surgery. 2003 Dec; 134(6):982-7; discussion 987-8.
          View in: PubMed
        51. Xu H, Elster EA, Blair PJ, Burkly LC, Tadaki DK, Harlan DM, Kirk AD. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant. 2003 Nov; 3(11):1350-4.
          View in: PubMed
        52. Digon BJ, Rother KI, Hirshberg B, Harlan DM. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care. 2003 Nov; 26(11):3191.
          View in: PubMed
        53. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, Harlan DM, Shalev A. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun. 2003 Oct 17; 310(2):641-5.
          View in: PubMed
        54. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003 Dec; 144(12):5149-58.
          View in: PubMed
        55. Hirshberg B, Preston EH, Xu H, Tal MG, Neeman Z, Bunnell D, Soleimanpour S, Hale DA, Kirk AD, Harlan DM. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. Transplantation. 2003 Jul 15; 76(1):55-60.
          View in: PubMed
        56. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15; 76(1):120-9.
          View in: PubMed
        57. Hirshberg B, Rother KI, Harlan DM. Islet transplantation: where do we stand now? Diabetes Metab Res Rev. 2003 May-Jun; 19(3):175-8; discussion 175.
          View in: PubMed
        58. Tadaki DK, Williams A, Lee KP, Kirk AD, Harlan DM. Porcine CD80: cloning, characterization, and evidence for its role in direct human T-cell activation. Xenotransplantation. 2003 May; 10(3):252-8.
          View in: PubMed
        59. Xu H, Montgomery SP, Preston EH, Tadaki DK, Hale DA, Harlan DM, Kirk AD. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol. 2003 Mar 1; 170(5):2776-82.
          View in: PubMed
        60. Pechhold K, Karges W, Blum C, Boehm BO, Harlan DM. Beta cell-specific CD80 (B7-1) expression disrupts tissue protection from autoantigen-specific CTL-mediated diabetes. J Autoimmun. 2003 Feb; 20(1):1-13.
          View in: PubMed
        61. Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression. J Clin Endocrinol Metab. 2002 Dec; 87(12):5424-9.
          View in: PubMed
        62. Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002 Nov 27; 74(10):1365-9.
          View in: PubMed
        63. Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC, Chamberlain CE, Polly SM, Harlan DM, Kirk AD. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002 Nov 23; 360(9346):1662-4.
          View in: PubMed
        64. Xu H, Tadaki DK, Elster EA, Burkly LC, Berning JD, Cruzata F, Kampen RL, Montgomery SP, Patterson NB, Harlan DM, Kirk AD. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 2002 Oct 15; 74(7):940-3.
          View in: PubMed
        65. Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology. 2002 Sep; 143(9):3695-8.
          View in: PubMed
        66. Chute JP, Saini AA, Chute DJ, Wells MR, Clark WB, Harlan DM, Park J, Stull MK, Civin C, Davis TA. Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow. Blood. 2002 Dec 15; 100(13):4433-9.
          View in: PubMed
        67. Shalev A, Blair PJ, Hoffmann SC, Hirshberg B, Peculis BA, Harlan DM. A proinsulin gene splice variant with increased translation efficiency is expressed in human pancreatic islets. Endocrinology. 2002 Jul; 143(7):2541-7.
          View in: PubMed
        68. Hirshberg B, Montgomery S, Wysoki MG, Xu H, Tadaki D, Lee J, Hines K, Gaglia J, Patterson N, Leconte J, Hale D, Chang R, Kirk AD, Harlan DM. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes. 2002 Jul; 51(7):2135-40.
          View in: PubMed
        69. Hoffmann SC, Stanley EM, Cox ED, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant. 2002 Jul; 2(6):560-7.
          View in: PubMed
        70. Harlan DM. Islet cell allotransplantation as a model system for a bioengineering approach to reparative medicine: immunological concerns. Ann N Y Acad Sci. 2002 Jun; 961:331-4.
          View in: PubMed
        71. Harlan DM, Metzger DW, Karp CL, Matzinger P, Munn DH, Ransohoff RM. Immune response to engineered tissues and cells: breakout session summary. Ann N Y Acad Sci. 2002 Jun; 961:350-1.
          View in: PubMed
        72. Harlan DM, Karp CL, Matzinger P, Munn DH, Ransohoff RM, Metzger DW. Immunological concerns with bioengineering approaches. Ann N Y Acad Sci. 2002 Jun; 961:323-30.
          View in: PubMed
        73. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8.
          View in: PubMed
        74. Montgomery SP, Mog SR, Xu H, Tadaki DK, Hirshberg B, Berning JD, Leconte J, Harlan DM, Hale D, Kirk AD. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant. 2002 Apr; 2(4):381-5.
          View in: PubMed
        75. Chute JP, Clark W, Saini A, Wells M, Harlan D. Rescue of hematopoietic stem cells following high-dose radiation injury using ex vivo culture on endothelial monolayers. Mil Med. 2002 Feb; 167(2 Suppl):74-7.
          View in: PubMed
        76. Xu H, Arnaud F, Tadaki DK, Burkly LC, Harlan DM, Kirk AD. Human platelets activate porcine endothelial cells through a CD154-dependent pathway. Transplantation. 2001 Dec 15; 72(11):1858-61.
          View in: PubMed
        77. Elster EA, Xu H, Tadaki DK, Montgomery S, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Marx R, Harlan DM, Kirk AD. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 2001 Nov 15; 72(9):1473-8.
          View in: PubMed
        78. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001 Oct 27; 72(8):1444-50.
          View in: PubMed
        79. Montgomery SP, Hale DA, Hirshberg B, Harlan DM, Kirk AD. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev. 2001 Oct; 183:214-22.
          View in: PubMed
        80. Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation. 2001 Aug 27; 72(4):720-6.
          View in: PubMed
        81. Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001 Aug 15; 72(3):377-84.
          View in: PubMed
        82. Kirk AD, Blair PJ, Tadaki DK, Xu H, Harlan DM. The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci. 2001 May 29; 356(1409):691-702.
          View in: PubMed
        83. Pechhold K, Patterson NB, Blum C, Fleischacker CL, Boehm BO, Harlan DM. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J Immunol. 2001 Feb 15; 166(4):2531-9.
          View in: PubMed
        84. Elster EA, Xu H, Tadaki DK, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Patterson NB, Harlan DM, Kirk AD. Primate skin allotransplantation with anti-CD154 monotherapy. Transplant Proc. 2001 Feb-Mar; 33(1-2):675-6.
          View in: PubMed
        85. Xu H, Elster E, Batty D, Berning J, Burkly L, Kampen R, Swanson S, Tadaki D, Harlan D, Kirk A. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc. 2001 Feb-Mar; 33(1-2):223-4.
          View in: PubMed
        86. Gaglia JL, Harlan DM. Transplantation tolerance. Curr Dir Autoimmun. 2001; 4:283-307.
          View in: PubMed
        87. Chute JP, Saini A, Wells M, Clark W, Wu A, St Louis D, Blair P, Harlan D, Kaushal S. Preincubation with endothelial cell monolayers increases gene transfer efficiency into human bone marrow CD34(+)CD38(-) progenitor cells. Hum Gene Ther. 2000 Dec 10; 11(18):2515-28.
          View in: PubMed
        88. Tadaki DK, Craighead N, Saini A, Celniker A, Burkly LC, Lee KP, Chute JP, Harlan DM, Kirk AD. Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. Transplantation. 2000 Jul 15; 70(1):162-7.
          View in: PubMed
        89. Blair PJ, Riley JL, Harlan DM, Abe R, Tadaki DK, Hoffmann SC, White L, Francomano T, Perfetto SJ, Kirk AD, June CH. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med. 2000 Feb 21; 191(4):651-60.
          View in: PubMed
        90. Herrera PL, Harlan DM, Vassalli P. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci U S A. 2000 Jan 4; 97(1):279-84.
          View in: PubMed
        91. Harlan DM, Kirk AD. The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA. 1999 Sep 15; 282(11):1076-82.
          View in: PubMed
        92. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A. 1999 Jul 6; 96(14):8132-7.
          View in: PubMed
        93. Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol. 1999 Jul; 29(7):2319-29.
          View in: PubMed
        94. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, Iaria G, Han D, Wagner JL, Ruiz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes. 1999 Jul; 48(7):1473-81.
          View in: PubMed
        95. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
          View in: PubMed
        96. Knechtle SJ, Kirk AD, Fechner JH, Hong X, Dong Y, Hamawy MM, Harlan DM. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Transplant Proc. 1999 May; 31(3B Suppl):27S-28S.
          View in: PubMed
        97. St Louis DC, Woodcock JB, Franzoso G, Blair PJ, Carlson LM, Murillo M, Wells MR, Williams AJ, Smoot DS, Kaushal S, Grimes JL, Harlan DM, Chute JP, June CH, Siebenlist U, Lee KP, Fransozo G. Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. J Immunol. 1999 Mar 15; 162(6):3237-48.
          View in: PubMed
        98. Saha B, Chattopadhyay S, Germond R, Harlan DM, Perrin PJ. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection. Eur J Immunol. 1998 Dec; 28(12):4213-20.
          View in: PubMed
        99. Sobel DO, Goyal D, Ahvazi B, Yoon JW, Chung YH, Bagg A, Harlan DM. Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J Autoimmun. 1998 Aug; 11(4):343-52.
          View in: PubMed
        100. Davis TA, Saini AA, Blair PJ, Levine BL, Craighead N, Harlan DM, June CH, Lee KP. Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J Immunol. 1998 Apr 15; 160(8):3689-97.
          View in: PubMed
        101. Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998 Mar 15; 160(6):2706-14.
          View in: PubMed
        102. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 5; 94(16):8789-94.
          View in: PubMed
        103. Pechhold K, Patterson NB, Craighead N, Lee KP, June CH, Harlan DM. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol. 1997 May 15; 158(10):4921-9.
          View in: PubMed
        104. Blair PJ, Riley JL, Carroll RG, St Louis DC, Levine BL, Saha B, Lee KP, Perrin PJ, Harlan DM, June CH. CD28 co-receptor signal transduction in T-cell activation. Biochem Soc Trans. 1997 May; 25(2):651-7.
          View in: PubMed
        105. Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol. 1996 Nov 1; 157(9):3869-75.
          View in: PubMed
        106. Saha B, Harlan DM, Lee KP, June CH, Abe R. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J Exp Med. 1996 Jun 1; 183(6):2675-80.
          View in: PubMed
        107. Imagawa A, Hanafusa T, Itoh N, Miyagawa J, Nakajima H, Namba M, Kuwajima M, Tamura S, Kawata S, Matsuzawa Y, Harlan DM. Islet-infiltrating t lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2). J Autoimmun. 1996 Jun; 9(3):391-6.
          View in: PubMed
        108. Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson NB, Gray GS, June CH. Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes. 1995 Jul; 44(7):816-23.
          View in: PubMed
        109. Harlan DM, Abe R, Lee KP, June CH. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin Immunol Immunopathol. 1995 May; 75(2):99-111.
          View in: PubMed
        110. Herrera PL, Harlan DM, Fossati L, Izui S, Huarte J, Orci L, Vassalli JD, Vassalli P. A CD8+ T-lymphocyte-mediated and CD4+ T-lymphocyte-independent autoimmune diabetes of early onset in transgenic mice. Diabetologia. 1994 Dec; 37(12):1277-9.
          View in: PubMed
        111. Harlan DM, Hengartner H, Huang ML, Kang YH, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, et al. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc Natl Acad Sci U S A. 1994 Apr 12; 91(8):3137-41.
          View in: PubMed
        112. Harlan DM, Graff JM, Stumpo DJ, Eddy RL, Shows TB, Boyle JM, Blackshear PJ. The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS). Analysis of its gene product, promoter, and chromosomal localization. J Biol Chem. 1991 Aug 5; 266(22):14399-405.
          View in: PubMed
        For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
        David's Networks
        Click the "See All" links for more information and interactive visualizations!
        Concepts
        _
        Co-Authors
        _
        Similar People
        _
        Same Department
        Physical Neighbors
        _

        This is an official Page/Publication of the University of Massachusetts Worcester Campus
        Office of the Vice Provost for Research, 55 Lake Ave North, Worcester, Massachusetts 01655
        Questions or Comments? Email: publicaffairs@umassmed.edu Phone: 508-856-1572